Bosutinib For Autosomal Dominant Polycystic Kidney Disease

NCT01233869 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Polycystic Kidney, Autosomal Dominant

Interventions

DRUG: Bosutinib
DRUG: Bosutinib
DRUG: Placebo

Sponsor

Pfizer